LARK advises IBA on the acquisition of PhantomX

IBA Dosimetry, a subsidiary of Ion Beam Applications (IBA), has acquired PhantomX, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence quality assurance.

Business Law Powerhouse LARK comprehensively advised IBA on this transaction with Max Hentrich (PICTURED), Dr. Daniel Gubitz, and Fabienne Pflug (all M&A/Corporate Law) as well as Dr. Tobias Stuppi and Jakob Heimrich (both Tax). In the area of IP/IT law, LARK was supported by Dr. Thomas Schafft of the Munich law firm SSH.

Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz, with support from Charité University Hospital in Berlin, PhantomX is active in the development of realistic models of human body parts that are used globally for validating diagnostic and therapeutic imaging systems, as well as medical education and training. PhantomX is at the forefront of quality assurance for AI applications in medical imaging and provides tools for AI-enhanced clinical solutions.

Belgium-based IBA is the world leader in particle accelerator technology and the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry.